Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al.
Josef S SmolenRémy MostardRobert B M LandewéPublished in: Annals of the rheumatic diseases (2020)